Terms: = Kidney tumors AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
42 results:
1. Inhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma.
Li W; Bano F; Khan A; Wei DQ; Alshammari A; Xu B; Wang Y
Comput Biol Med; 2023 Sep; 164():107257. PubMed ID: 37527610
[TBL] [Abstract] [Full Text] [Related]
2. Relationships Between Urinary and Nonurinary Symptoms in Treatment-Seeking Women in LURN.
Smith AR; Mansfield SA; Bradley CS; Kenton KS; Helmuth ME; Cameron AP; Kirkali Z; Bretschneider CE; Andreev V; Sarma A; Lane G; Collins SA; Cella D; Lai HH; Harte SE; Griffith JW;
Urogynecology (Phila); 2024 Feb; 30(2):123-131. PubMed ID: 37428882
[TBL] [Abstract] [Full Text] [Related]
3. Adaptive Immunity in Genitourinary Cancers.
Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
[TBL] [Abstract] [Full Text] [Related]
4. A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.
Hu Y; Xu S; Qi Q; Wang X; Meng J; Zhou J; Hao Z; Liang Q; Feng X; Liang C
Front Public Health; 2022; 10():989566. PubMed ID: 36276376
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Dong P; Zhang X; Peng Y; Zhang Y; Liu R; Li Y; Pan Q; Wei W; Guo S; Zhang Z; Han H; Zhou F; Liu Y; He L
Clin Cancer Res; 2022 Nov; 28(21):4807-4819. PubMed ID: 36074152
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study.
Lim AR; Kim JH; Hyun MH; Kim YH; Lee S
Support Care Cancer; 2022 Oct; 30(10):8129-8137. PubMed ID: 35779133
[TBL] [Abstract] [Full Text] [Related]
7. System analysis of
Situ Y; Xu Q; Deng L; Zhu Y; Gao R; Lei L; Shao Z
Int J Biol Markers; 2022 Mar; 37(1):90-101. PubMed ID: 34870494
[TBL] [Abstract] [Full Text] [Related]
8. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma.
Khanna P; Soh HJ; Chen CH; Saxena R; Amin S; Naughton M; Joslin PN; Moore A; Bakouny Z; O'Callaghan C; Catalano P; Signoretti S; McKay R; Choueiri TK; Bhasin M; Walther T; Bhatt RS
Sci Transl Med; 2021 Jan; 13(577):. PubMed ID: 33472951
[TBL] [Abstract] [Full Text] [Related]
9. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract] [Full Text] [Related]
10. A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology-A Pilot Cohort Study.
Gomes-Lima CJ; Auh S; Thakur S; Zemskova M; Cochran C; Merkel R; Filie AC; Raffeld M; Patel SB; Xi L; Wartofsky L; Burman KD; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2020; 11():53. PubMed ID: 32132976
[No Abstract] [Full Text] [Related]
11. Updates on the Management of Thyroid Cancer.
Araque KA; Gubbi S; Klubo-Gwiezdzinska J
Horm Metab Res; 2020 Aug; 52(8):562-577. PubMed ID: 32040962
[TBL] [Abstract] [Full Text] [Related]
12. Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer.
Matrone A; Ceccarini G; Beghini M; Ferrari F; Gambale C; D'Aqui M; Piaggi P; Torregrossa L; Molinaro E; Basolo F; Vitti P; Santini F; Elisei R
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31875910
[TBL] [Abstract] [Full Text] [Related]
13. Molecular pathways related to the control of proliferation and cell death in 786-O cells treated with plumbagin.
Mancilla IA; Coatti GC; Biazi BI; Zanetti TA; Baranoski A; Marques LA; Corveloni AC; Lepri SR; Mantovani MS
Mol Biol Rep; 2019 Dec; 46(6):6071-6078. PubMed ID: 31456160
[TBL] [Abstract] [Full Text] [Related]
14. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.
Wang Q; Luo M; Wei N; Chang A; Luo KQ
Mol Pharm; 2019 Sep; 16(9):3873-3886. PubMed ID: 31389706
[TBL] [Abstract] [Full Text] [Related]
15. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD; Santegoets SJAM; Harting J; Baars A; van Ham SM; Scheper RJ; Hooijberg E; de Gruijl TD; van den Eertwegh AJM
Cancer Immunol Immunother; 2019 Jun; 68(6):1025-1035. PubMed ID: 30852622
[TBL] [Abstract] [Full Text] [Related]
16. Incidence of Diabetes Mellitus, Cardiovascular Diseases, and Cancer in Patients Undergoing Malabsorptive Surgery (Biliopancreatic Diversion and Biliointestinal Bypass) vs Medical Treatment.
Pontiroli AE; Ceriani V; Sarro G; Micheletto G; Giovanelli A; Zakaria AS; Fanchini M; Osio C; Nosari I; Veronelli AM; Folli F;
Obes Surg; 2019 Mar; 29(3):935-942. PubMed ID: 30448983
[TBL] [Abstract] [Full Text] [Related]
17. Effect of Treatment Modality on Long Term Renal Functions in Patients With Muscle Invasive Bladder Cancer.
Hamidi N; Suer E; Ozkidik M; Gokce MI; Ozturk E; Ozcan C; Turkolmez K; Beduk Y; Baltaci S
Urol J; 2019 Jun; 16(3):274-278. PubMed ID: 30345496
[TBL] [Abstract] [Full Text] [Related]
18. Non-α-fetoprotein-producing adrenal hepatoid adenocarcinoma: A case report and literature review.
Lin J; Cao Y; Yu L; Lin L
Medicine (Baltimore); 2018 Sep; 97(39):e12336. PubMed ID: 30278510
[TBL] [Abstract] [Full Text] [Related]
19. [Computer-assisted laparoscopic surgery for renal carcinoma].
Alyaev YG; Sirota ES; Bezrukov EA; Sukhanov RB
Urologiia; 2018 Jul; (3):30-38. PubMed ID: 30035415
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive Genomic Profiling of Metastatic tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
[TBL] [Abstract] [Full Text] [Related]
[Next]
